



CSL Limited
ABN: 99 051 588 348
655 Elizabeth Street
Melbourne
Victoria 3000 Australia
T +613 9389 1911
F +613 9389 1434
[CSL.com](https://www.csl.com)

ASX Announcement

For immediate release

8 April 2024

Publication of AEGIS II Trial Data

Further to the announcement lodged with the ASX on 12 February 2024, attached are the links to the publications of the primary data and secondary analyses as presented to the American College of Cardiology yesterday.

CSL will continue to assess the data produced by the AEGIS II trial but reiterates that it has no near term plans for a regulatory filing.

New England Journal of Medicine: <https://www.nejm.org/doi/full/10.1056/NEJMoa2400969>

Journal of the American College of Cardiology: <https://www.jacc.org/doi/10.1016/j.jacc.2024.03.396>

Authorised by:

Fiona Mead

Company Secretary

For further information, please contact:

Investors:

Bernard Ronchi

Investor Relations

CSL Limited

P: +61 3 9389 3470

E: bernard.ronchi@csl.com.au

Media:

Bernadette Murdoch

Communications

CSL Limited

P: +61 449 950 745

E: Bernadette.murdoch@csl.com.au